Related Experiment Video

Updated: Jul 4, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Her2 cross talk and therapeutic resistance in breast cancer

Laura M Bender1, Rita Nahta

  • 1Department of Pharmacology, School of Medicine, Winship Cancer Institute, Emory University, Atlanta, GA 30322-1013, USA.

Frontiers in Bioscience : a Journal and Virtual Library
|May 30, 2008
PubMed

Insights

HER2 receptor cross talk with estrogen receptors and other growth factors can cause resistance to breast cancer therapies like trastuzumab. Understanding these interactions may lead to new treatments for HER2-overexpressing cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • HER2 (Human Epidermal growth factor Receptor 2) is overexpressed in about 30% of metastatic breast cancers.
  • HER2 receptor signaling can interact with other growth factor pathways, potentially leading to resistance against cancer therapies.

Purpose of the Study:

  • This review examines the cross talk between the HER2 receptor and the estrogen receptor.
  • It also explores mechanisms of resistance to HER2-targeted therapies, such as trastuzumab.

Main Methods:

  • The review synthesizes existing research on HER2 receptor interactions.
  • It discusses signaling pathways including the PI3-kinase pathway and cross talk with the insulin-like growth factor-I receptor.

Main Results:

  • HER2 cross talk with estrogen receptors contributes to resistance to endocrine therapies.
  • Resistance to trastuzumab can occur through HER family signaling, PI3-kinase pathway activation, and IGF-I receptor cross talk.

Conclusions:

  • Understanding HER2 receptor cross talk is crucial for developing novel therapeutic strategies.
  • This knowledge can inform the development of new treatments for HER2-overexpressing breast cancers.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...